Need Immediate Care?

Find Urgent Care Locations

General Inquiries: 775-982-4100
Billing: 775-982-4130

Pembrolizumab in Combination with Sacituzumab Govitecan-hziy vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer

Short Title: EA8231

Enrollment Status: Recruiting

NCT #: NCT06524544

Specialty Area: Oncology

Condition Studied: Urothelial Cancer

Age Groups: Adult; Older Adult

Study Information

Summary / Purpose

The purpose of this study is to compare the usual treatment of chemotherapy to using pembrolizumab plus Sacituzumab govitecan-hziy for patients with urothelial cancer. The combination of pembrolizumab and Sacituzumab govitecan-hziy could shrink your cancer or prevent it from growing.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Confirmed locally advanced or metastatic urothelial cancer
Must have measurable disease
Must have had at least 1 line of systemic therapy given

What's Involved

Participation in the study will include:

Random assignment to receive either pembrolizumab plus sacituzumab govitecan, both given intravenously (IV), or standard IV chemotherapy chosen by your doctor
Standard IV chemotherapy, which may include cisplatin or carboplatin with gemcitabine, docetaxel, or paclitaxel, for participants assigned to that group
Imaging with computed tomography (CT) scans or magnetic resonance imaging (MRI) scans
Sample collection for research
Completing questionnaires about your bladder cancer symptoms, fatigue, and quality of life

Principal Investigator

Shi-Ming Tu, MD

Hematology - Oncology

Renown Hematology/Oncology

(775) 982–5000

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06524544

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.